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The contribution of left ventricular diastolic dysfunction to
the impairment in overall left ventricular performance in
patients with systolic dysfunction is underappreciated.
This article summarizes the available data on diastolic
dysfunction in patients with congestive heart failure in
which the predominant abnormality was thought to be left
ventricular systolic dysfunction. The prevalence and iden-
tification of diastolic abnormalities and their clinical rele-
vance are addressed, particularly the role of ß-adrenergic
blocking therapy. The potential benefits of ß-adrenergic
blocking therapy to diastolic performance are discussed
from both a hemodynamic and clinical standpoint, with
the implication that diastolic performance and its modula-
tion should be considered in future investigations. (CHF.
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Congestive heart failure is known to be caused by ei-
ther left ventricular systolic dysfunction or diastolic
dysfunction in patients with preserved left ventricular
systolic performance. This differentiation in the
pathophysiology of the clinical syndrome of conges-
tive heart failure and the medical management of each
of these unique hemodynamic conditions has been
well described.1–4 However, despite the reports of ab-
normalities in left ventricular diastolic performance in
patients with congestive heart failure who do not have
left ventricular systolic dysfunction,5,6 no study has
critically evaluated the prevalence, significance, and
management of diastolic abnormalities in patients with
left ventricular systolic dysfunction. Furthermore, the
contribution of impairment in left ventricular diastolic
performance in patients with impaired left ventricular
systolic performance, as defined by a left ventricular
ejection fraction of 40% or less, is underappreciated.
The development of novel therapeutic strategies
aimed at the biologic properties of the failing heart
through the use of ß-adrenergic blocking therapy in
chronic congestive heart failure7,8 has rekindled an
interest in the investigation of diastole. This article
summarizes the available data on diastolic dysfunc-
tion in the presence of congestive heart failure in
which left ventricular systolic dysfunction is assumed
to predominate, with particular emphasis on the
methods of assessment and response to ß-adrenergic
blocking therapy. In particular, the following questions
will be addressed: 1) How often is diastolic dysfunction
present when left ventricular systolic performance is
impaired? 2) How do we identify diastolic dysfunction?
3) Is there any prognostic significance to impaired di-
astolic performance in this setting? and 4) Does med-
ical therapy, principally β-adrenergic blockade, have
a beneficial impact on abnormal left ventricular dias-
tolic properties?
Diastolic Abnormalities in 
Congestive Heart Failure
In 1975, Waagstein and associates9 provided evidence
that left ventricular diastolic dysfunction exists in the
setting of congestive heart failure due predominantly
to left ventricular systolic dysfunction when they
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demonstrated a strikingly prominent A wave and
elevation of left ventricular end-diastolic pressure that
subsequently improved with metoprolol therapy. Subse-
quent hemodynamic studies revealed a decrease in
heart rate and left ventricular end-diastolic pressure
with an associated increase in left ventricular ejection
fraction with ß-adrenergic blocking therapy.10,11 Other
studies have assessed left ventricular diastolic filling as
an index of hemodynamic impairment.12–16 Diastolic
abnormalities were shown to correlate with symp-
toms,12,13 left ventricular filling pressures,14 and clini-
cal outcomes,13,15,16 such as death and transplantation.
These investigations of left ventricular diastolic filling
primarily involved noninvasive echocardiographic
techniques, which are well reviewed in the literature.17
Echocardiographic Assessment
of Diastolic Performance
The evaluation of left ventricular diastolic performance
typically begins with a Doppler echocardiographic ex-
amination of transmitral inflow velocities.18,19 Pul-
monary venous flow velocities can also be used as an
adjunct to the transmitral inflow velocities to assess fill-
ing pressures. Hemodynamic changes associated with
advanced left ventricular diastolic dysfunction include
an increased E wave (early) velocity, decreased A wave
velocity (due to atrial contraction), and shortened de-
celeration time of the E wave velocity. Four distinct 
filling patterns (normal, delayed relaxation, pseudo-
normalized, and restrictive) have been described, rep-
resenting the progression from normal to severe left
ventricular diastolic dysfunction with increasing left
ventricular chamber stiffness and high left ventricular
filling pressures. These four phases describe a continu-
um of left ventricular diastolic dysfunction. As these
echocardiographic phases progress in severity, the
prognosis worsens.
When normal left ventricular filling is compro-
mised, Doppler echocardiographic transmitral inflow
velocities in the early stages reveal impaired left ven-
tricular relaxation, as evidenced by a decrease in early
transmitral inflow velocity (E wave) and an increased
component of filling attributable to a greater depen-
dence of left ventricular diastolic filling on atrial con-
traction (A wave). With progressive deterioration of left
ventricular diastolic performance, the increasing left
ventricular chamber stiffness and increasing left atrial
pressure can result in a “pseudonormal” filling pat-
tern, which can be unmasked by an assessment of the
pulmonary venous velocities and through the use of
the Valsalva maneuver. As left ventricular diastolic per-
formance worsens, the most severe pattern is represen-
tative of restrictive physiology characterized by a rapid
early filling component, a shortened deceleration time
of the E wave velocity, a very stiff left ventricle with
marked elevation in filling pressures, and a poor prog-
nosis in terms of mortality and need for transplanta-
tion. Two newer echocardiographic modalities to
assess left ventricular diastolic filling and performance
are color kinesis and tissue Doppler imaging, but these
have not yet become widely available.
Clinical data to support the use of echocardiograph-
ic techniques for assessing both the progression of left
ventricular systolic and diastolic dysfunction20 and the
response to medical therapy21 have been reported. In
one study,21 reversion of the restrictive pattern, initially
identified in 19 patients at baseline, was associated with
a reduction in pulmonary capillary wedge pressure
and improvement in exercise capacity following 6
months of medical therapy. In the six patients who ini-
tially had a nonrestrictive pattern at baseline and then
developed a restrictive pattern, these hemodynamic
features significantly deteriorated. In addition, pro-
gression to death or cardiac transplantation occurred
in 35% of patients with a persistent restrictive pattern,
5% with a reversible restrictive pattern, and 4% with a
persistent nonrestrictive pattern.
Despite technical advances in the echocardiograph-
ic evaluation of left ventricular diastolic performance,
significant potential problems in techniques, measure-
ment, and reporting should be noted.22 Furthermore,
the potential for poor correlation with invasive descrip-
tors of left ventricular diastolic performance and the
confounding effects produced by changes in left ven-
tricular preload, afterload, and heart rate on transmi-
tral inflow velocities should always be considered.23
ß-Adrenergic Blocking Therapy:
Insights into Modulation of Left
Ventricular Diastolic Performance
In the late 1980s, the possibility that β-adrenergic re-
ceptor antagonists could modify left ventricular dias-
tolic performance and that β-adrenergically mediated
myocardial relaxation was attenuated in heart failure
stimulated active investigation.24 Further insights were
provided into the improvement in left ventricular dias-
tolic properties with the consistent finding of a de-
crease in left ventricular end-diastolic pressure in the
hemodynamic studies10,11 that followed Waagstein’s
initial report in 1975.9 In addition, chronic ß-adrener-
gic blocking therapy was associated with improvement
in the invasively determined time constant of exponen-
tial left ventricular pressure decay (tau), which is repre-
sentative of early/active left ventricular relaxation.10
Noninvasive measurements of transmitral inflow veloc-
ities during ß-adrenergic blockade showed an increase
in the E wave deceleration time,25,26 which had been
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shown to predict left ventricular chamber stiffness.27
Both the improvement in tau and the increase in
echocardiographically demonstrated deceleration time
from the early transmitral inflow velocity suggested im-
proved left ventricular diastolic performance.
One noninvasive study28 did not find an effect on
left ventricular diastolic performance with carvedilol
therapy, perhaps because of the limitations of noninva-
sive assessments of left ventricular diastolic properties.
In general, there appears to be supporting evidence for
improved left ventricular diastolic performance in pa-
tients with left ventricular systolic dysfunction treated
with ß-adrenergic blocking agents. Furthermore, it ap-
pears that patients with the highest left ventricular
end-diastolic pressures and most prolonged isovolu-
metric relaxation times may benefit the most from
ß-adrenergic blocking therapy.29 This finding strongly
suggests the importance of diastolic modulation in the
remarkable success of ß-adrenergic blocking therapy 
in the treatment of patients with congestive heart fail-
ure, even in the presence of left ventricular systolic
dysfunction.
ß-Adrenergic Blocking Therapy
and Congestive Heart Failure
Nearly every placebo-controlled trial of ß-adrenergic
blocking therapy of greater than 3 months’ duration
has demonstrated improvement in left ventricular sys-
tolic performance.8 More prolonged therapy results in
reverse remodeling, consisting of a regression in my-
ocardial mass and normalization of left ventricular
shape, which is partly a reversal of the cardiomyopathic
phenotype.7,30 Given these changes in the phenotype
with ß-adrenergic blocking therapy, the possibility of
improved clinical outcome exists. Traditional prog-
nostic factors for clinical outcomes, such as progression
to death or cardiac transplantation, have included 
left ventricular ejection fraction and total body peak
oxygen consumption on exercise testing.
The clinical and echocardiographic data at the
time of clinical presentation, such as the New York
Heart Association functional class, left ventricular
ejection fraction, and the various echocardiographic
parameters of diastolic filling, were shown to be inde-
pendently associated with subsequent progression to
death or transplantation.31 In that investigation, 197
patients with dilated cardiomyopathy of both ischemic
and nonischemic origin were assessed to derive a risk
stratification score based on readily available clinical
and echocardiographic parameters at the time of clin-
ical presentation. According to stepwise regression
analyses, age, echocardiographically derived peak E
wave velocity, left ventricular ejection fraction, and
systolic blood pressure independently predicted car-
diac death. Similarly, the New York Heart Association
functional class, left ventricular ejection fraction, the
echocardiographically derived E/A wave ratio, and
systolic blood pressure were independently associated
with cardiac death or the need for cardiac transplan-
tation. All of these clinical variables except for age
can be affected by ß-adrenergic blocking therapy.
The general consensus from the clinical trials32–38
involving ß-adrenergic blockade in the treatment
of patients with left ventricular systolic dysfunc-
tion is that the clinical benefits include decreased
mortality, reduction in morbidity, and a tendency to-
ward improvement of heart failure symptoms and
exercise capacity. A greater mortality benefit is seen
with ß-adrenergic blocking therapy in these patients
than with treatment by angiotensin-converting enzyme
inhibitors. This benefit of ß-adrenergic blocking thera-
py is also additive to the angiotensin-converting enzyme
inhibitors, with the combined effect being greater than
that of either alone.7
Hemodynamic Mechanism of
Improvement in Left Ventricular
End-Diastolic Pressure
The hemodynamic mechanism of the ß-adrenergic
blocking therapy-induced improvement in left ven-
tricular end-diastolic pressure, which can be used as a
surrogate marker of left ventricular diastolic 
dysfunction in patients with congestive heart failure,
presumably due to left ventricular systolic dysfunction,
is unclear. We investigated the effects of metoprolol
therapy on left ventricular diastolic performance in
18 patients (four patients served as controls) with
idiopathic dilated cardiomyopathy to determine
whether left ventricular diastolic dysfunction coex-
ists in the setting of left ventricular systolic dysfunction,
as defined by a left ventricular ejection fraction of 40%
or less, and to assess the relationship between the
decrease in left ventricular end-diastolic pressure and
the modulation of left ventricular diastolic properties
with metoprolol therapy.39 We also sought to determine
if the anticipated improvement in left ventricular dias-
tolic performance with ß-adrenergic blocking therapy
was independent or related to the changes in left 
ventricular systolic performance.
Left ventricular diastolic properties were assessed 
invasively, both before and following 6 months of meto-
prolol therapy (145±70 mg/day in two doses), with 
simultaneous micromanometry and biplane cineven-
triculography. In the metoprolol-treated group, the
heart rate and left ventricular end-diastolic pressure de-
creased significantly, the left ventricular ejection 
fraction and systolic arterial pressure increased signifi-
cantly, and indices of left ventricular contractility im-
proved significantly (Table). These findings were
similar to those previously reported.39 In patients who
received metoprolol, all of the assessed left ventricular
diastolic properties, i.e., isovolumic relaxation rate
(tau), left ventricular chamber stiffness constant, left
ventricular volume elastance, and myocardial stiffness
constant, improved (Figs. 1 and 2). A multiple regres-
sion analysis revealed that the decrease in left ventricu-
lar end-diastolic pressure was a result of significant
improvement in both early/active left ventricular relax-
ation (tau) and late/passive left ventricular relaxation
(myocardial stiffness). The benefits on chamber stiffness
and volume elastance were determined by improve-
ment in the myocardial stiffness constant. Importantly,
this suggested that the improvement in chamber com-
pliance was not due to extraneous influences, e.g., ve-
nous return or pericardial restraint. The increase in the
left ventricular ejection fraction was due to improve-
ment in contractility. No improvement was seen in the
control patients. These data indicate that improvement
in left ventricular systolic performance occurs indepen-
dently of improvement in left ventricular diastolic per-
formance in response to ß-adrenergic blocking therapy.
In addition, although both early/active and late/passive
left ventricular relaxation contribute to improvement in
left ventricular end-diastolic pressure, improvements
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TABLE. HEMODYNAMIC INDICES
PATIENT HR LVEDP LVSP DV ESV EF (+)dP/dtmax (+)dP/dtmax/EDV LV MASS
PRE POST PRE POST PRE POST PRE POST PRE POST PRE POST PRE POST PRE POST PRE POST
METOPROLOL-TREATED CARDIOMYOPATHY PATIENTS
1 65 47 24 18 134 139 254 247 185 160 27.2 35.2 747 928 2.94 3.76 219 296
2 95 55 32 11 119 126 239 197 180 91 24.7 53.8 817 863 3.42 4.38 226 229
3 80 62 31 24 108 153 178 159 115 86 35.4 45.9 841 1161 4.72 7.30 137 209
4 107 83 26 12 96 99 494 358 382 255 22.7 28.8 835 827 1.69 2.31 281 199
5 92 54 15 14 101 128 219 139 143 51 34.7 63.3 623 1374 2.84 9.88 227 147
6 88 80 5 9 103 121 177 187 100 116 43.5 38.0 827 1096 4.67 5.86 124 160
7 49 60 21 12 134 126 221 169 120 95 43.1 43.8 1192 1258 5.65 7.44 167 186
8 79 73 17 16 98 103 140 146 74 81 47.2 44.5 776 1160 4.79 4.28 159 126
9 72 85 16 12 114 109 415 346 272 229 34.5 33.8 609 744 1.47 2.15 175 223
10 87 88 13 9 110 113 262 191 168 78 35.9 59.2 1032 1047 3.94 5.48 287 222
11 80 83 12 10 114 122 200 215 104 66 48.0 69.3 1295 1592 6.48 7.40 205 170
12 86 60 29 15 88 95 600 250 503 164 16.2 34.4 498 711 0.83 2.84 345 316
13 83 84 23 9 116 134 347 252 240 159 30.8 36.9 836 996 2.41 3.95 302 247
14 70 70 28 12 111 106 429 399 344 337 19.8 15.5 688 676 1.57 1.69 384 425
Mean 81 70 21 13 110 120 298 233 209 141 33.1 43.0 830 1031 3.39 4.91 231 225
SD 14 14 8 4 13 16 138 82 126 83 10.1 14.5 218 265 1.71 2.42 79 78
CONTROL CARDIOMYOPATHY PATIENTS
1 90 79 24 22 140 171 278 174 200 207 28.1 24.5 904 1195 3.25 4.36 211 198
2 82 67 18 19 105 106 427 377 287 252 32.8 33.2 648 587 1.52 1.56 191 245
3 75 83 35 28 104 90 379 372 288 279 24.0 25.0 655 678 1.73 1.82 171 220
4 77 96 21 20 137 124 339 271 217 175 36.0 35.4 1233 1284 3.64 4.74 198 176
Mean 81 81 25 22 122 123 356 324 248 228 30.2 29.5 860 936 2.53 3.12 193 210
SD 7 12 7 4 20 35 63 59 46 46 5.3 5.6 276 354 1.07 1.66 17 30
HR=heart rate (beats/min); LVEDP=left ventricular end-diastolic pressure (mm Hg); LVSP=left ventricular 
systolic pressure (mm Hg); EDV=end diastolic volume (ml); ESV=end-systolic volume (ml); EF=left ventricular
ejection fraction (%); (+)dP/dtmax=peak positive dP/dt (mm Hg/sec); (+)dP/dtmax/EDV=peak positive dP/dt/EDV (mm
Hg/sec/ml); LV mass=left ventricular mass (g)
Figure 1. Early/active isovolumic left ventricular relax-
ation measures are improved with metprolol therapy. Tln
and Td=relaxation constants.
documented by each invasive measurement of left ven-
tricular diastolic performance occur independently.
Whether or not there is a temporal dissociation in the
benefits derived from ß-adrenergic blocking therapy on
left ventricular systolic and diastolic performance was
not answered by this investigation, although it has been
suggested that they are.25
Clinical Implications
The significance of this invasive hemodynamic investi-
gation is that a strong relationship exists between the
salutary effects of metoprolol therapy on left ventricu-
lar end-diastolic pressure, early/active isovolumic re-
laxation, and late/passive myocardial relaxation. Of
particular note is that these effects occurred in addition
to the beneficial effects of metropolol on the left ven-
tricular ejection fraction and contractility.
This somewhat parallel but independent improve-
ment in left ventricular systolic and diastolic perfor-
mance has also been detected by echocardiographic
techniques.25 Our investigation of the hemodynamic
mechanism underlying the reduction in left ventricular
end-diastolic pressure with ß-adrenergic blocking ther-
apy also lends support to the finding of hemodynamic
benefits occurring in both diastole and systole in pa-
tients with left ventricular systolic dysfunction, al-
though they may be temporally disconnected.
Given that both left ventricular contractility and
early/active isovolumic and late/passive myocardial
relaxation are improved following ß-adrenergic
blocking therapy, a potential unifying pathophysio-
logic mechanism may involve an effect of this therapy
on abnormal calcium homeostasis in the cardiomyo-
pathic myocyte. Abnormal calcium homeostasis possi-
bly contributes to the hemodynamic correlates of
increased myocardial stiffness, delayed isovolumic re-
laxation, and decreased contractility. The improve-
ments in both left ventricular systolic and diastolic
performance seen in this study, as in others, is consis-
tent with the concept of ß-adrenergic blocking thera-
py beneficially affecting calcium homeostasis.
Prevalence of Diastolic 
Dysfunction in the 
Presence of Left Ventricular 
Systolic Dysfunction
Returning to the issue of the prevalence of left ventricu-
lar diastolic dysfunction in patients with left ventricular
systolic dysfunction, analysis of our data reveals that di-
astolic abnormalities are potentially very significant and
common. In this small group of 14 cardiomyopathy pa-
tients, if a left ventricular end-diastolic pressure of 15
mm Hg or more was used as an index of left ventricular
diastolic dysfunction, 11/14 patients (79%) could be con-
sidered to have diastolic abnormalities. If we use a more
specific hemodynamic marker, such as the myocardial
stiffness constant at a cut-off value of 6 or more, then the
prevalence of left ventricular diastolic dysfunction de-
creases to 8/14 patients (57%). However, this still sug-
gests that abnormalities in left ventricular diastolic
properties are common in patients with left ventricular
systolic dysfunction. These abnormalities in diastole can
be readily assessed via noninvasive and invasive hemo-
dynamic techniques. Each of these techniques has limi-
tations, yet each has value, especially given the fact that
noninvasive characterization of left ventricular diastolic
properties has proven prognostic value and has been
shown to correlate with clinical outcomes if it indicates
improvement with medical therapy. 
Conclusions
The beneficial effects of ß-adrenergic blocking therapy
in patients with ischemic or nonschemic cardiomyopa-
thy due to left ventricular systolic dysfunction with or
without concomitant diastolic dysfunction are clear, as
manifested by an increase in left ventricular ejection
fraction and a decrease in left ventricular end-diastolic
pressure. These systolic-diastolic interactions may be
connected through the ß-adrenergic blocking effects
on calcium homeostasis. The exact prevalence of left
ventricular diastolic abnormalities in patients with left
ventricular systolic dysfunction is unknown and re-
quires further investigation. However, preliminary data
would suggest that this is common.39 The mechanisms
of the beneficial effects of ß-adrenergic blockade in pa-
tients with left ventricular systolic dysfunction possibly
include hemodynamic improvement in left ventricular
diastolic properties, as demonstrated by favorable ef-
fects on early/active isovolumic and late/passive my-
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Figure 2. Late/passive myocardial relaxation properties
are beneficially affected by metoprolol therapy. k=left ven-
tricular chamber stiffness constant; k1=left ventricular
volume elastance; ke=myocardial stiffness constant.
K (ml-1) K1 Ke
ocardial relaxation. The left ventricular end-diastolic
pressure can be viewed as a marker for left ventricular
diastolic dysfunction, which is potentially amenable to
alteration with ß-adrenergic blocking therapy. The po-
tential importance of left ventricular diastolic perfor-
mance and its modulation, and its relationship to
improvement in left ventricular systolic performance,
quality of life, and exercise performance, should be
considered in future investigations.
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